logo

Urogen Pharma Ltd. (URGN)



Trade URGN now with
  Date
  Headline
1/8/2019 8:10:19 AM UroGen Announces Results Of UGN-101 From Phase 3 OLYMPUS Trial For The Non-Surgical Treatment Of Patients With LG UTUC
1/3/2019 6:33:07 AM UroGen Pharma Appoints Elizabeth Barrett As President And CEO
12/17/2018 8:22:31 AM UroGen Begins Rolling Submission Of NDA For UGN-101 For Treatment Of Low-Grade Upper Tract Urothelial Cancer
11/12/2018 8:13:38 AM UroGen Pharma Q3 Loss/shr $1.28 Vs. Loss/shr $0.02 Prior Year
10/30/2018 8:07:57 AM FDA Grants Breakthrough Therapy Designation For UroGen Pharma’s UGN-101 For LG UTUC
8/14/2018 7:03:31 AM UroGen Pharma Posts Q2 Net Loss Of $18.0 Mln Or $1.14 Per Share
7/11/2018 8:03:34 AM UroGen Pharma Submits IND Application For UGN-102 (VesiGel™)
6/5/2018 8:06:54 AM UroGen Pharma Appoints Stephen Mullennix As Interim CFO And Jason Patel As VP Of Finance
5/21/2018 2:46:21 PM UroGen Pharma Announces Positive Interim Results From Pivotal Phase 3 OLYMPUS Trial Of UGN-101
5/15/2018 8:06:55 AM UroGen Pharma Posts Q1 Net Loss Of $13.4 Mln Or $0.88 Per Share
4/3/2018 8:37:01 AM UroGen Announces Presentation Of Results From Interim Analysis Of Pivotal Phase 3 OLYMPUS Trial Of UGN-101
3/15/2018 7:07:07 AM UroGen Pharma Q4 Net Loss $10.07 Mln Or $0.74/Shr Vs Income $12.9 Mln Or $1.56/Shr Last Year
2/14/2018 8:05:00 AM UroGen Pharma Appoints Stephen Mullennix As COO